Tom West Joins Inogen’s Board of Directors

Inogen Inc. has appointed Tom West to Inogen’s Board of Directors. Kristen Miranda, who has served as a board director since March 2021, has retired.
 
“We are pleased to welcome Tom West to the Inogen Board. Tom brings additional general management and operational experience to the Inogen Board with his history of leadership and business success in medical technology and life sciences healthcare spaces,” Inogen Board Chair Elizabeth Mora said. “Under the leadership of Nabil Shabshab, Inogen’s president and CEO, we have made significant progress in rebuilding Inogen into a medtech company that is capable of delivering durable growth as we successfully execute on our strategic initiatives, advance our prescriber growth strategy and drive productivity and efficiency of our commercial operations. The addition of Tom West will further elevate the partnership between the board and the executive team to advance Inogen’s transformation into a global respiratory care leader. On behalf of the Board of Directors, I would also like to thank Kristen Miranda for her commitment and many valuable contributions to the Board. She has brought a lot of experience and thought partnership around the healthcare space and channel dynamics, specifically around the aspects of consumer health.”
 
Tom West is president, CEO, and an executive board director at Nalu Medical Inc., a privately held medical technology company focused on neurostimulation to treat chronic intractable pain. He joined Nalu in August 2022. Before joining Nalu, West served from 2019 to 2022 as president, CEO, and director at Intersect ENT Inc., a publicly traded medical device and drug delivery company in the sinus surgery space. Intersect ENT was acquired by Medtronic in May of 2022, doubling its enterprise value in less than three years despite the COVID-19 pandemic. Prior to Intersect, West was worldwide president, Diagnostic Solutions, at Hologic from 2015 to 2019. West began his healthcare career at Johnson & Johnson, where he assumed roles of increasing responsibility over a 23-year tenure including worldwide president of Strategy and Business Development for the J&J Family of Diabetes Solutions Companies, division president of LifeScan North America, and division president of LifeScan Europe, Middle East, and Africa.
 
West was an independent board member at Orthofix from 2021 to 2023. He has also been a board member at medical technology trade associations, AdvaMed and Biocom California. West earned a bachelor of arts degree in politics and economics from Princeton University and an MBA from the University of Pennsylvania, Wharton School.
 
“I am thrilled to have the opportunity to advance Inogen’s transformation into a global respiratory care leader,” West stated. “I look forward to adding my operating experience accelerating growth opportunities to help the company enhance the value it delivers to its patients, customers and shareholders.”
 
In connection with the appointment, West will be joining the board’s Compliance Committee as well as the Nominating and Governance Committee.
 
Inogen Inc. offers respiratory products for use in the homecare setting. Inogen develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.